gasguide

Cisatracurium

Nimbex

Benzylisoquinolinium non-depolarizing neuromuscular blocker (intermediate duration)

Competitive antagonist at the post-synaptic nicotinic ACh receptor at the neuromuscular junction. Single cis-cis isomer of atracurium (4× more potent, lower laudanosine production).

Indications

  • Neuromuscular blockade for intubation + maintenance
  • Preferred when renal/hepatic dysfunction, patients without IV access for sugammadex, organ donor procurement

Dosing

ContextAdultPediatric
Intubation (2× ED95)0.15–0.20 mg/kg IV0.10–0.15 mg/kg IV (age 2–12)
Maintenance bolus0.03 mg/kg IV q20–30 min
Continuous infusion1–3 mcg/kg/min after recovery to T11.0–2.0 mcg/kg/min

Pharmacokinetics

Onset 2–3 min (slower than rocuronium 1–2 min). Duration of intubating dose ~45–60 min. Eliminated by HOFMANN ELIMINATION (spontaneous, pH+temperature-dependent breakdown in plasma at body pH/37°C). Independent of hepatic + renal clearance — the unique property that drives ICU + organ-failure use. Hofmann produces laudanosine (CNS stimulant at very high cumulative doses; clinically irrelevant with cis vs older atracurium).

Hemodynamic effects

Hemodynamically inert at clinical doses — no significant histamine release (unlike older atracurium), no autonomic effects, no HR/BP changes. The cleanest cardiovascular profile of any NMB.

Side effects

  • !Slower onset than rocuronium (not preferred for true RSI)
  • !No sugammadex reversal — must wait for spontaneous recovery or use neostigmine
  • !Laudanosine accumulation with very prolonged infusions (days) — theoretical seizure risk, not seen clinically with cis
  • !Slight precipitation with alkaline drugs (propofol) — flush line between

Contraindications

  • ×Known hypersensitivity (rare)

Reversal / antidote

Neostigmine 0.04–0.07 mg/kg IV + glycopyrrolate 0.01 mg/kg (or atropine) once TOF count ≥ 2/4. Sugammadex DOES NOT reverse cisatracurium (only aminosteroids: roc, vec, panc).

Clinical pearls

  • Drug of choice when both renal AND hepatic function are impaired or unknown (organ failure ICU patient, transplant recipient, sepsis with multi-organ dysfunction).
  • Hofmann elimination: NMB clearance unaffected by perfusion, hepatic blood flow, dialysis status — predictable offset.
  • ED95 ~0.05 mg/kg; intubating dose is 2–4× ED95; bolus + infusion strategy avoids histamine that older atracurium produced.
  • Stored refrigerated (4°C); discard if shaken vigorously or warmed > 25°C × prolonged period (Hofmann begins in the syringe).
  • If you need RSI (60-sec onset) AND sugammadex reversibility: use rocuronium, not cisatracurium.
Education only — confirm against current package inserts and institutional protocols. Doses assume normal organ function unless otherwise noted.